GLP-1 maintenance dosing: what trials show

A recurring question in GLP-1 communities is what dose to settle on after the weight-loss phase ends. Approved prescribing information for semaglutide and tirzepatide describes a titration schedule that ends at a defined maximum, not a separate "maintenance dose." Whether a patient continues at the maximum tolerated dose, steps down, or eventually stops is a clinical decision that the trials have now begun to inform, though the evidence is still accumulating^[1].

What approved labels actually say about dose

The Mounjaro prescribing information (tirzepatide, approved for type-2 diabetes) describes a starting dose of 2.5 mg weekly, increasing in 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly in adults^[1]. The label does not define a lower "maintenance phase" dose. Patients who reach their glycaemic or weight target are expected to stay on whatever dose achieved that outcome, up to the 15 mg ceiling.

Semaglutide's Wegovy label for chronic weight management follows the same logic: a 16-week dose escalation ending at 2.4 mg weekly, which is the maintenance dose for adults in that indication^[2]. For type-2 diabetes, Ozempic reaches a maximum of 2 mg weekly. The concept of titrating down after reaching a weight target is not part of either product's labelled dosing schedule.

What the trials show about continuing versus stopping

The clearest data point on what happens when you stop comes from SURMOUNT-4, the discontinuation sub-trial of the tirzepatide obesity programme. Participants who had lost a mean 20.9% of body weight over 36 weeks on tirzepatide were then randomised to continue tirzepatide or switch to placebo for a further 52 weeks. Those who continued gained 5.5% of body weight back; those who switched to placebo regained 14.8%^[3]. Participants on continued tirzepatide ended the study 19.4% below their baseline weight, versus 9.9% below baseline in the placebo group.

STEP-4 ran an analogous experiment with semaglutide. Adults who had been on semaglutide 2.4 mg for 20 weeks were randomised to continue or to switch to placebo for a further 48 weeks. The continuation group kept losing weight; the placebo group regained most of what they had lost^[2]. The pattern is consistent across both molecules: the weight-loss mechanism depends on the drug remaining in the system.

The NIDDK, the US federal body responsible for diabetes and digestive and kidney diseases, reflects this in its patient guidance: indefinite use is presented as a reasonable option for people who have achieved a health benefit and are tolerating the medication. It also states plainly that some weight will return after stopping.

Dose reduction after reaching a target weight

Community discussions often ask whether stepping down from the maximum dose is feasible once weight loss stabilises. The approved labels do not include a formal step-down protocol. What is documented: the minimum effective dose for glycaemic control in the tirzepatide T2D programme was 5 mg, and the 10 mg and 15 mg doses produced progressively greater weight loss but also more gastrointestinal side effects. For some patients, a lower dose within the approved range may balance tolerability and efficacy differently than the maximum dose.

That said, no large randomised trial has published a formal comparison of step-down versus continuation at maximum dose for maintenance. The existing trial data, from SURMOUNT-4 for tirzepatide and STEP-4 for semaglutide, compared continuation at the therapeutic dose against complete discontinuation. They do not answer what happens at, say, 5 mg tirzepatide versus 15 mg tirzepatide in the long run.

Retatrutide and the missing maintenance data

For retatrutide the situation is simpler to state and harder to work with: there is no approved label. Retatrutide is investigational and not approved by the FDA, EMA, MHRA or any national agency we track^[4]. TRIUMPH-1, the phase 3 obesity trial, reported a 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. No discontinuation sub-trial equivalent to SURMOUNT-4 has yet been published for retatrutide. Any community discussion of retatrutide maintenance dosing is therefore speculative relative to an unapproved investigational compound.

What this means in practice

The trial evidence collectively points in one direction: GLP-1 class drugs in the approved obesity indications are not a course of treatment with a clear end point. They are closer to antihypertensives or statins, where the physiological benefit is present while the drug is active and begins to reverse on discontinuation. The question of which dose to maintain on, whether to step down, and when (or whether) to eventually stop belongs with a prescribing clinician who can weigh the individual cardiovascular risk profile, side-effect burden, and access constraints. The community discussion on [r/Peptides] captures the real-world variation: individual responses differ widely, and anecdotal dose-finding in online communities is not a substitute for the clinical titration process.

This article is for educational and journalistic purposes. It does not constitute medical advice. Decisions about GLP-1 dosing, dose reduction, or discontinuation should be made with a healthcare provider who knows your history.